{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:09Z","timestamp":1787021049103,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014592","name":"Insulet Corporation","doi-asserted-by":"publisher","award":["B81A2221-4FA2-4630-916B-371A3ACBD00A"],"award-info":[{"award-number":["B81A2221-4FA2-4630-916B-371A3ACBD00A"]}],"id":[{"id":"10.13039\/100014592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Insulin pump therapy (IPT) improves glucose control in people with type 1 diabetes (T1D) compared with multiple daily injections (MDI). However, their size, the tethered insulin infusion set, intrusiveness when operating the device and the need to disconnect during showering limit their acceptance to many who may benefit. The Omnipod DASH\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Insulin Management System is a small waterproof tubeless device which is wirelessly controlled by a handheld device which may be an acceptable alternative. However, there are no randomised controlled trials focusing on the impact on user perceptions of tubeless insulin pump therapy. This pilot study aims to assess study feasibility and acceptability of patch pump therapy compared with usual care in adults with T1D in Australia to inform power calculations and progression to a large-scale multi-site randomised controlled study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A pilot multi-site parallel randomised controlled study will be conducted in sixty-four adults with T1D who are managed on MDI or IPT and self-monitoring with finger-stick blood glucose from four specialist diabetes centres in Victoria, Australia. Following carbohydrate counting education, participants will be randomised to use Omnipod DASH\n                      <jats:sup>\u00ae<\/jats:sup>\n                      System (Omnipod group) or continue usual care (usual care group) for 12\u00a0weeks, followed by a 12-week extension phase where all participants will use Omnipod DASH\n                      <jats:sup>\u00ae<\/jats:sup>\n                      System. The primary outcome measure is feasibility determined by study completion rates with a threshold of 0.80. Acceptability of the intervention (Omnipod DASH\n                      <jats:sup>\u00ae<\/jats:sup>\n                      System) will be assessed by the difference in Diabetes Technology Questionnaire \u2018current\u2019 (DTQ-current) score at 12\u00a0weeks post-randomisation compared to baseline. Secondary outcomes will include other measures of user acceptance, process outcomes, resource outcomes, participant-centred outcomes, healthcare professional perceptions and glycaemic outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This pilot study will provide insights regarding the feasibility of the study design and the first data regarding user acceptance of insulin patch pump technology in Australian T1D adults. We anticipate that this study will provide information informing the design of a larger study evaluating the impact of patch pumps on subjective outcomes that are of significance to the person living with T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Australian New Zealand Clinical Trials Registry (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/anzctr.org.au\/\">https:\/\/anzctr.org.au\/<\/jats:ext-link>\n                      ) ACTRN12621001195842 (8th September 2021). Please refer to Additional file 1: Appendix 1 for full details.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-023-01400-4","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T04:12:31Z","timestamp":1696824751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A pilot randomised controlled parallel arm trial evaluating treatment satisfaction with the Omnipod DASH\u00ae Insulin Management System compared with usual care in adults with type 1 diabetes in Australia: rationale, study design and methodologies"],"prefix":"10.1186","volume":"9","author":[{"given":"Yee Wen","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Kiburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Trawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Partovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryn","family":"Roem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiros","family":"Fourlanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif I.","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-4032","authenticated-orcid":false,"given":"David N.","family":"O\u2019Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"2","key":"1400_CR1","first-page":"93","volume":"13","author":"P Karagianni","year":"2009","unstructured":"Karagianni P, Sampanis C, Katsoulis C, Miserlis G, Polyzos S, Zografou I, et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Hippokratia. 2009;13(2):93\u20136.","journal-title":"Hippokratia"},{"issue":"14","key":"1400_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2017.13994","volume":"318","author":"B Karges","year":"2017","unstructured":"Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358\u201366.","journal-title":"JAMA"},{"issue":"9","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00592-019-01326-5","volume":"56","author":"L Pala","year":"2019","unstructured":"Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019;56(9):973\u201380.","journal-title":"Acta Diabetol"},{"issue":"3","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/ds18-0091","volume":"32","author":"C Berget","year":"2019","unstructured":"Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes Spectr. 2019;32(3):194\u2013204.","journal-title":"Diabetes Spectr"},{"key":"1400_CR5","doi-asserted-by":"publisher","first-page":"109000","DOI":"10.1016\/j.diabres.2021.109000","volume":"179","author":"JC Lu","year":"2021","unstructured":"Lu JC, Vogrin S, McAuley SA, Lee MH, Paldus B, Bach LA, et al. Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Res Clin Pract. 2021;179:109000.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"1400_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1177\/1932296817702656","volume":"11","author":"KD Barnard","year":"2017","unstructured":"Barnard KD, Wysocki T, Ully V, Mader JK, Pieber TR, Thabit H, et al. Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. J Diabetes Sci Technol. 2017;11(6):1080\u20138.","journal-title":"J Diabetes Sci Technol"},{"key":"1400_CR7","volume-title":"Insulin pump use in Australia","author":"Australian Institute of Health and Welfare","year":"2012","unstructured":"Australian Institute of Health and Welfare. Insulin pump use in Australia. Canberra: AIHW; 2012."},{"issue":"Suppl 1","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.2337\/dc21-S002","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabet Care. 2021;44(Suppl 1):S15\u2013s33.","journal-title":"Diabet Care"},{"key":"1400_CR9","unstructured":"National Diabetes Services Scheme. Changes to the NDSS 2022. 2022. Available from: https:\/\/www.ndss.com.au\/about-the-ndss\/changes-to-the-ndss."},{"issue":"12","key":"1400_CR10","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.2337\/dc06-1134","volume":"29","author":"D Deiss","year":"2006","unstructured":"Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730\u20132.","journal-title":"Diabetes Care"},{"issue":"10057","key":"1400_CR11","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr\u00f6ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet (London, England). 2016;388(10057):2254\u201363.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"1400_CR12","doi-asserted-by":"publisher","first-page":"e14756","DOI":"10.1111\/dme.14756","volume":"39","author":"S Rose","year":"2022","unstructured":"Rose S, Styles SE, Wiltshire EJ, Stanley J, Galland BC, de Bock MI, et al. Use of intermittently scanned continuous glucose monitoring in young people with high-risk type 1 diabetes-extension phase outcomes following a 6-month randomized control trial. Diabet Med. 2022;39(5):e14756.","journal-title":"Diabet Med"},{"issue":"1","key":"1400_CR13","doi-asserted-by":"publisher","first-page":"e000025","DOI":"10.1136\/bmjdrc-2014-000025","volume":"2","author":"KD Barnard","year":"2014","unstructured":"Barnard KD, Wysocki T, Allen JM, Elleri D, Thabit H, Leelarathna L, et al. Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care. 2014;2(1):e000025.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1089\/dia.2010.0015","volume":"12","author":"JDRF Continuous Glucose Monitoring Study Group","year":"2010","unstructured":"JDRF Continuous Glucose Monitoring Study Group. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther. 2010;12(9):679\u201384.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"1400_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00592-021-01789-5","volume":"59","author":"BJ Wheeler","year":"2022","unstructured":"Wheeler BJ, Collyns OJ, Meier RA, Betts ZL, Frampton C, Frewen CM, et al. Improved technology satisfaction and sleep quality with Medtronic MiniMed\u00ae Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 diabetes in a randomized crossover trial. Acta Diabetol. 2022;59(1):31\u20137.","journal-title":"Acta Diabetol"},{"issue":"Supplement_1","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20142021. Diabetes Care. 2020;44(Supplement_1):S73\u201384.","journal-title":"Diabetes Care"},{"issue":"10","key":"1400_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dme.12453","volume":"31","author":"M Peyrot","year":"2014","unstructured":"Peyrot M, Xu Y, Rubin RR. Development and validation of the diabetes medication system rating questionnaire-short form. Diabet Med. 2014;31(10):1237\u201344.","journal-title":"Diabet Med"},{"key":"1400_CR18","first-page":"40","volume":"4","author":"M Schrepp","year":"2017","unstructured":"Schrepp M, Hinderks A, Thomaschewski J. Construction of a benchmark for the User Experience Questionnaire (UEQ). Int J Interact Multimed Artif Intell. 2017;4:40\u20134.","journal-title":"Int J Interact Multimed Artif Intell"},{"issue":"1","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1541931213571043","volume":"57","author":"SC Peres","year":"2013","unstructured":"Peres SC, Pham T, Phillips R. Validation of the System Usability Scale (SUS):SUS in the wild. Proc Hum Factors Ergon Soc Annu Meet. 2013;57(1):192\u20136.","journal-title":"Proc Hum Factors Ergon Soc Annu Meet"},{"key":"1400_CR20","unstructured":"Clarke V, Braun V. Thematic analysis: a practical guide. Sage Publications; 2022. Accessed from: https:\/\/us.sagepub.com\/en-us\/nam\/thematic-analysis\/book248481."},{"issue":"1","key":"1400_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(17)30411-4","volume":"6","author":"C Farrington","year":"2018","unstructured":"Farrington C. Access to diabetes technology: the role of clinician attitudes. Lancet Diabetes Endocrinol. 2018;6(1):15.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1400_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/dia.2019.0380","volume":"22","author":"C Farrington","year":"2020","unstructured":"Farrington C, Hovorka R, Murphy HR. Who should access closed-loop technology? A qualitative study of clinician attitudes in England. Diabetes Technol Ther. 2020;22(5):404\u201310.","journal-title":"Diabetes Technol Ther"},{"issue":"8","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593\u2013603.","journal-title":"Diabetes Care"},{"issue":"7","key":"1400_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2337\/dc15-2716","volume":"39","author":"DM Maahs","year":"2016","unstructured":"Maahs DM, Buckingham BA, Castle JR, Cinar A, Damiano ER, Dassau E, et al. Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care. 2016;39(7):1175\u20139.","journal-title":"Diabetes Care"},{"key":"1400_CR25","volume-title":"The FreeStyle Libre Pro System: a clinical overview of accuracy","author":"Abbott Diabetes Care","year":"2017","unstructured":"Abbott Diabetes Care. The FreeStyle Libre Pro System: a clinical overview of accuracy. California: Abbott Diabetes Care; 2017."},{"issue":"11","key":"1400_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/dia.2014.0378","volume":"17","author":"T Bailey","year":"2015","unstructured":"Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787\u201394.","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"1400_CR27","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/dom.14815","volume":"24","author":"KK Hood","year":"2022","unstructured":"Hood KK, Garcia-Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, et al. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obes Metab. 2022;24(12):2309\u201318.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1400_CR28","doi-asserted-by":"publisher","first-page":"e15020","DOI":"10.1111\/dme.15020","volume":"40","author":"E Kubilay","year":"2022","unstructured":"Kubilay E, Trawley S, Ward GM, Fourlanos S, Grills CA, Lee MH, et al. Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial. Diabet Med. 2022;40(4):e15020.","journal-title":"Diabet Med"},{"issue":"9","key":"1400_CR29","doi-asserted-by":"publisher","first-page":"e14907","DOI":"10.1111\/dme.14907","volume":"39","author":"A Roberts","year":"2022","unstructured":"Roberts A, Fried L, Dart J, de Bock M, Fairchild J, King B, et al. Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes. Diabet Med. 2022;39(9):e14907.","journal-title":"Diabet Med"},{"issue":"2","key":"1400_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2337\/dc20-1060","volume":"44","author":"Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group","year":"2021","unstructured":"Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group. A randomized clinical trial assessing continuous glucose monitoring (CGM) use with standardized education with or without a family behavioral intervention compared with fingerstick blood glucose monitoring in very young children with type 1 diabetes. Diabet Care. 2021;44(2):464\u201372.","journal-title":"Diabet Care"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-023-01400-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:30:49Z","timestamp":1700580649000},"score":1,"resource":{"primary":{"URL":"https:\/\/pilotfeasibilitystudies.biomedcentral.com\/articles\/10.1186\/s40814-023-01400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1186\/s40814-023-01400-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2381611\/v1","asserted-by":"object"}]},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be conducted in accordance with guidelines for Good Clinical Practice (GCP) and the Declaration of Helsinki. All potential participants will be provided with written and verbal information regarding the study, the procedures involved and all potential risks related to participating. A study investigator will obtain written informed consent from each participant prior to commencing study procedures. The participant will be provided with a copy of the signed consent form.The study has received approval from an independent research ethics committee at the lead clinical site. No individual data will be identified. The ethics approval number is HREC 101\/21. Any substantial amendments to the study protocol will be reported to the independent ethics committees for approval prior to implementation, updated on the ANZCTR, and the study investigators will be advised in writing. Safety and progress reports will be sent to the HREC. Reports will be forwarded to the HREC at least annually and within 3\u00a0months of study completion.The study will be sponsored and indemnified by St Vincent\u2019s Hospital Melbourne. This sponsor had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data or decision to submit results.Sponsor Reference: SVHM 101\/21Contact name: Dr. Megan Robertson MBBS FRACP FANZCA FCICMAddress: Group Chief Research Officer, St Vincent\u2019s Health Australia; PO Box 2900; 41 Victoria Parade, Fitzroy VIC 3065.Telephone:\u2009+\u200961 3 9288 3895Email: megan.robertson@svha.org.au","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DNO has received honoraria from Medtronic, Insulet, Abbott, Novo and Sanofi; research support from Medtronic, Insulet, Dexcom, Roche, GlySense, BioCapillary and Endogenex; and is on Advisory Boards for Medtronic, Insulet, Abbott, Ypsomed, Novo and Sanofi.EIE\u2019s institution has received research funding from Eli Lilly, Boehringer-Ingelheim, Novo Nordisk and Pharmasol. EIE has received funding for honoraria for speakers and advisory fees from Abbott, Bayer and Sanofi, and the money received is directly donated to EIE\u2019s institution for diabetes research.SF has received honoraria for speaker fees for AstraZeneca, Boehringer-Ingelheim, Lilly and Novo Nordisk and honoraria for advisor fees for Medtronic, Mylan, Pfizer and Sanofi.ST reports nonfinancial support from Abbott Diabetes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}